Full-Time

Senior Financial Analyst

Healthcare Specialties Group

Posted on 5/16/2026

Henry Schein

Henry Schein

10,001+ employees

Global healthcare product distributor and services

Compensation Overview

$83k - $114.2k/yr

+ Bonus

Remote in USA

Remote

Travel typically less than 10%.

Category
Finance & Banking (1)
Required Skills
Power BI
Forecasting
Oracle
Excel/Numbers/Sheets
Financial Modeling
Requirements
  • Typically 5 to 7 or more years of increasing responsibility in terms of any applicable professional experience.
  • Typically a Bachelor's Degree or global equivalent in related discipline. Master's degree or global equivalent a plus.
  • Solid understanding of budgeting, forecasting, financial reporting, financial policies and procedures, systems implementation, and process improvement.
  • Advanced proficiency in MS Excel, including development of complex financial models, multi-dimensional data analysis, pivot tables, advanced formulas, scenario analysis, and automation to support reporting and forecasting.
  • Experience with MS Power BI, including data modeling, dashboard development and maintenance, advanced visualizations, and leading the transition from Excel-based reporting to automated, scalable BI solutions.
  • Working knowledge of Oracle PBCS, HFM, SmartView, and related financial systems is highly beneficial.
  • Travel typically less than 10%.
Responsibilities
  • Perform Henry Schein Products OTD daily and monthly financial reporting across all sales channels and Product Business Units (PBUs). Track performance versus budget and forecast, identify key drivers and variances, and recommend corrective actions.
  • Perform monthly reconciliations of OTD sales and gross profit data across financial systems and business dashboards to ensure data accuracy, consistency, and alignment.
  • Participate in the annual budget process for Henry Schein Products, including building and maintaining standardized Excel-based submission templates, partnering with local business teams to develop detailed financial projections, and reviewing year-over-year variances for reasonableness and alignment with business assumptions.
  • Assist with the development of an improved forecast process for Henry Schein Products OTD sales and gross profit.
  • Lead and support the transition of OTD monthly reporting from Excel-based models to MS Power BI and other technology-enabled solutions, ensuring data integrity and improved visualization and accessibility.
  • Assist with Oracle PBCS integration initiatives across HSG, including data validation, reporting alignment, and process standardization.
  • Prepare and support monthly and quarterly financial presentations for management, translating complex financial data into clear, concise insights.
  • Support ad-hoc financial analyses and special projects as needed.
  • Continuously evaluate and improve reporting, forecasting, and analytical processes; recommend and implement automation and efficiency enhancements where possible.
  • Develop and maintain strong working relationships across the HSG portfolio and cross-functional teams.
  • Meet company standards related to the quality, accuracy, and timeliness of work on an ongoing basis.
  • Perform all duties in compliance with Company policies, procedures, and Worldwide Business Standards.
  • Adhere to standards of professional workplace behavior in completing job duties and assignments.
Desired Qualifications
  • Master's degree or global equivalent in related discipline; may hold one or more industry certifications; professional certification may be required to advance.

Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Huntington, New York

Founded

1932

Simplify Jobs

Simplify's Take

What believers are saying

  • Value Creation Plan targets over $200 million operating income improvement.
  • U.S. e-commerce rollout completion by August 2026 should boost ordering efficiency.
  • Gross margin expanded 28 basis points through private-label mix and dynamic pricing.

What critics are saying

  • Oil-driven freight and product inflation pressures margins if pricing lags.
  • Medical sales remain lumpy after a weak 2026 flu season.
  • Leadership transition and board shrinkage complicate execution of the margin plan.

What makes Henry Schein unique

  • World’s largest office-based dental and medical solutions provider.
  • Q1 2026 sales reached $3.37 billion, up 6.3% year over year.
  • High-growth businesses now generate nearly half of operating income.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Henry Schein who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Parental Leave

Short Term Disability

Health Savings Account/Flexible Spending Account

Education Benefits

Company News

Yahoo Finance
Apr 9th, 2026
Henry Schein board to shrink from 15 to 10 members as Stanley Bergman retires after 44 years

Henry Schein has announced its board will shrink from 15 to 10 members following its 2026 annual meeting, with longtime director and former chairman Stanley Bergman retiring after 44 years alongside four other directors not standing for re-election. The board reshaping coincides with Frederick Lowery's appointment as chief executive, effective March 2026, framing the changes as part of a broader leadership transition. This governance shift adds uncertainty to Henry Schein's ongoing transformation, which includes a push towards higher-margin software and specialty products alongside cost-saving initiatives driven by KKR. Analysts project $14.8 billion revenue and $595.4 million earnings by 2029. The company's narrative suggests continued focus on digital offerings, specialty products and international expansion under new leadership.

Fortune
Mar 27th, 2026
South African expat built $13B Fortune 500 firm fleeing apartheid at 26

Stanley Bergman, who fled apartheid South Africa at 26, stepped down this month as CEO of Henry Schein after 36 years leading the company. He transformed the regional dental supplier from $225 million in revenue to a $13.2 billion Fortune 500 medical and dental distributor. Bergman joined as CFO in 1980, attracted by the founders' commitment to aligning business with social values. Under his leadership, Henry Schein appeared on Fortune's World's Most Admired Companies list for 21 consecutive years. His leadership philosophy emphasised hiring for character over credentials, diversifying perspectives, expanding through joint ventures, and serving society alongside stakeholders. The company's "Give Kids a Smile" initiative provides free dental screenings to over 300,000 children annually. Fred Lowery succeeded Bergman as CEO on 2 March, with Bergman remaining chairman.

Yahoo Finance
Mar 6th, 2026
$13.2B healthcare supplier Henry Schein opens training centre and showroom in Southlake

Henry Schein, a $9 billion global healthcare supplier, has opened its first integrated training facility in Southlake, Texas. The Dallas Discovery Center spans 8,300 square feet at 1080 S. Kimball Ave., featuring eight experience labs, two training rooms, a boardroom and an attached warehouse. The facility serves as both a training centre for sales associates and a showroom for potential clients. It includes fully equipped dental labs, an ambulatory surgery room, 3D printing stations, sterilisation equipment and a functioning laboratory with blood-drawing and diagnostic tools. Henry Schein, headquartered in Melville, New York, recorded $13.2 billion in sales across 34 countries in 2025. The company previously opened an 811,000-square-foot distribution centre in Alliance in 2024. New CEO Frederick Lowery attended the facility's opening on 2nd March.

Business Wire
Mar 3rd, 2026
Henry Schein to present at Leerink and Barclays healthcare conferences in March

Henry Schein, the world's largest provider of healthcare solutions to office-based dental and medical practitioners, will present at two investor conferences in March. The company will appear at Leerink's Global Healthcare Conference in Miami on 9 March at 10:00 EST and Barclays 28th Annual Global Healthcare Conference on 10 March at 10:30 EST. Both presentations will be available via live webcast on the company's website, with replays accessible afterwards. Henry Schein, a FORTUNE 500 company headquartered in Melville, New York, operates in 34 countries and serves over one million customers globally. The company reported sales of $13.2 billion in 2025.

Yahoo Finance
Feb 26th, 2026
Henry Schein price targets lifted to $87–$104 as dental demand shows rebound

Henry Schein's assessed fair value has risen to $83.21 from $78.14, aligning with multiple analyst upgrades that lifted price targets to the $87–$100 range. Several firms, including Baird, Evercore ISI and JPMorgan, raised targets following improved dental demand indicators and Q4 results. Baird cited three consecutive months of modest patient demand rebound and forecast double-digit earnings growth starting in 2027, lifting its target to $104. However, UBS, Mizuho and Leerink maintained cautious neutral ratings despite modest target increases to $87–$88. The company appointed Frederick Lowery as CEO effective 2 March 2026, whilst Stanley Bergman transitions to Chairman after 35 years. Henry Schein guided 2026 sales growth of 3–5% and repurchased 2.8 million shares for $200 million.